Celldex Therapeutics Q4 Loss Widens, But Revenues Beat View - Quick Facts

(RTTNews) - Celldex Therapeutics, Inc. (CLDX) reported net loss for the fourth quarter of $31.82 million or $0.36 per share, wider than net loss of $22.06 million or $0.27 per share for the year-ago quarter.

Total revenue for the quarter grew to $1.48 million from $620 thousand in the prior-year quarter.

On average, analysts polled Thomson Reuters expected the company to report loss of $0.35 per share for the quarter on revenue of $390,000. Analysts' estimates typically exclude special items.

The increase in the revenues was primarily due to the company's clinical trial collaboration with BMS and its Rockefeller University services agreement.

Looking ahead, Celldex Therapeutics said it expects its cash, cash equivalents and marketable securities to be sufficient to fund its operating expenses and capital expenditure requirements through 2016.

However, the company noted this could be impacted by clinical data results from the Rintega program and their potential impact on its pace of commercial manufacturing and the rate of expansion of its commercial operations.